.: DERLEME
Metabolik Sendrom ve İşitme Kaybı Arasında İlişki: Literatür Eşliğinde
Relationship Metabolic Syndrome and Hearing Loss: Review of Literature
Turkiye Klinikleri J Intern Med. 2020;5(2):70-3
doi: 10.5336/intermed.2019-72374
Makale Dili: TR
Tam Metin
Ücretsiz Erişim
ÖZET
Metabolik sendrom (Met S); etiyopatogenezi tam olarak bilinmese de, insülin direnci zemininde gelişen abdominal obezite, glukoz intoleransı veya diabetes mellitus (DM), dislipidemi, hipertansiyon (HT) gibi sistemik bozuklukların birbirine eklendiği bir risk faktörleri topluluğudur. Tip 2 DM ve aterosklerotik hastalıkların en önemli ve en sık görülen nedenleri arasında yer alır. Gelişmekte olan ve gelişmiş ülkelerde sedanter yaşamın artması, beslenme alışkanlıklarındaki yanlış seçimler nedeniyle obezite sıklığı giderek artmakta, dolayısıyla metabolik sendrom insidansı da yükselmektedir. Kardiyovasküler, metabolik ve hepatik komplikasyonlar yanısıra ,işitme ile ilgili problemler de dahil olmak üzere multisistemik sorunlara yolaçabilen hayati bir bozukluktur. Tedavi yaklaşımları öncelikle yaşam tarzi değişikliği ile kilo vermenin sağlanması, kan basıncının regüle edilmesi, düzenli egzersiz, dislipidemi ve açlık kan şekerine yönelik beslenme önerileri, bu değişiklikler yeterli gelmezse farmakolojik tedavi seçeneklerini içermektedir. İşitme kaybı genetik sebepler yanısıra yaşlanma, gürültü maruziyeti, enfeksiyonlar gibi çeşitli çevresel faktörlere bağlı gelişebilen bir sağlık sorunudur. İşitme kaybı günlük yaşam kalitesini, psikososyal hayatı olumsuz yönde direk etkileyen sık ve önemli bir problemdir. Literatürde genel populasyonda yaygın ve kronik olan bu sorunun metabolik sendromla direk ilişkili olabileceğini gösteren bazı çalışmalar mevcuttur. Bu derlemede metabolik sendromla işitme kaybı arasında ilişki literatür eşliğinde incelenecek ve risk faktörlerini hedefleyen tedavi yaklaşımlarından bahsedilecektir.
Anahtar Kelimeler: Metabolik sendrom; işitme kaybı; risk faktörleri; tedavi
Metabolik sendrom (Met S); etiyopatogenezi tam olarak bilinmese de, insülin direnci zemininde gelişen abdominal obezite, glukoz intoleransı veya diabetes mellitus (DM), dislipidemi, hipertansiyon (HT) gibi sistemik bozuklukların birbirine eklendiği bir risk faktörleri topluluğudur. Tip 2 DM ve aterosklerotik hastalıkların en önemli ve en sık görülen nedenleri arasında yer alır. Gelişmekte olan ve gelişmiş ülkelerde sedanter yaşamın artması, beslenme alışkanlıklarındaki yanlış seçimler nedeniyle obezite sıklığı giderek artmakta, dolayısıyla metabolik sendrom insidansı da yükselmektedir. Kardiyovasküler, metabolik ve hepatik komplikasyonlar yanısıra ,işitme ile ilgili problemler de dahil olmak üzere multisistemik sorunlara yolaçabilen hayati bir bozukluktur. Tedavi yaklaşımları öncelikle yaşam tarzi değişikliği ile kilo vermenin sağlanması, kan basıncının regüle edilmesi, düzenli egzersiz, dislipidemi ve açlık kan şekerine yönelik beslenme önerileri, bu değişiklikler yeterli gelmezse farmakolojik tedavi seçeneklerini içermektedir. İşitme kaybı genetik sebepler yanısıra yaşlanma, gürültü maruziyeti, enfeksiyonlar gibi çeşitli çevresel faktörlere bağlı gelişebilen bir sağlık sorunudur. İşitme kaybı günlük yaşam kalitesini, psikososyal hayatı olumsuz yönde direk etkileyen sık ve önemli bir problemdir. Literatürde genel populasyonda yaygın ve kronik olan bu sorunun metabolik sendromla direk ilişkili olabileceğini gösteren bazı çalışmalar mevcuttur. Bu derlemede metabolik sendromla işitme kaybı arasında ilişki literatür eşliğinde incelenecek ve risk faktörlerini hedefleyen tedavi yaklaşımlarından bahsedilecektir.
Anahtar Kelimeler: Metabolik sendrom; işitme kaybı; risk faktörleri; tedavi
ABSTRACT
Metabolic syndrome (Met S); although its etiopathogenesis is not fully known, it is a collection of risk factors that combine insulin resistance with abdominal obesity, glucose intolerance or diabetes mellitus (DM), dyslipidemia and hypertension (HT). It is among the most important and most common causes of atherosclerotic diseases and Type 2 DM. The incidence of obesity is increasing in developing and developed countries due to the increase in sedentary life and wrong choices in feeding habits, thus increasing the incidence of metabolic syndrome. Cardiovascular, metabolic and hepatic complications, as well as a life problem that may cause a multisystem disorders, including problems related to hearing. Treatment approaches include weight gain through lifestyle change, regulation of blood pressure, regular exercise, nutrition recommendations for dyslipidemia and fasting blood sugar, and pharmacological treatment options if these changes do not suffice. Hearing loss is a health problem that may develop due to various environmental factors such as aging, noise exposure, infections as well as genetic causes. Hearing loss is the quality of life, psychosocial life directly affects negatively and is often a major problem.There are some studies in the literature showing that this common and chronic problem may be directly related to metabolic syndrome in the general population. In this review, the relationship between metabolic syndrome and hearing loss will be examined in the light of literature and treatment approaches targeting risk factors will be discussed.
Keywords: Metabolic syndrome; hearing loss; risk factors; therapy
Metabolic syndrome (Met S); although its etiopathogenesis is not fully known, it is a collection of risk factors that combine insulin resistance with abdominal obesity, glucose intolerance or diabetes mellitus (DM), dyslipidemia and hypertension (HT). It is among the most important and most common causes of atherosclerotic diseases and Type 2 DM. The incidence of obesity is increasing in developing and developed countries due to the increase in sedentary life and wrong choices in feeding habits, thus increasing the incidence of metabolic syndrome. Cardiovascular, metabolic and hepatic complications, as well as a life problem that may cause a multisystem disorders, including problems related to hearing. Treatment approaches include weight gain through lifestyle change, regulation of blood pressure, regular exercise, nutrition recommendations for dyslipidemia and fasting blood sugar, and pharmacological treatment options if these changes do not suffice. Hearing loss is a health problem that may develop due to various environmental factors such as aging, noise exposure, infections as well as genetic causes. Hearing loss is the quality of life, psychosocial life directly affects negatively and is often a major problem.There are some studies in the literature showing that this common and chronic problem may be directly related to metabolic syndrome in the general population. In this review, the relationship between metabolic syndrome and hearing loss will be examined in the light of literature and treatment approaches targeting risk factors will be discussed.
Keywords: Metabolic syndrome; hearing loss; risk factors; therapy
REFERANSLAR:
- Yasir HE, Tahir OA, Leena BM, Imam SN. Metabolic syndrome and its association with obesity and lifestyle factors in Sudanese population.Diabetes Metab Syndr. 2016;10(3):128-31. [Crossref] [PubMed]
- Türkiye Endokrinoloji ve Metabolizma Derneği Metabolik Sendrom Çalışma Grubu. METABOLİK SENDROM KILAVUZU. 2009.
- Ebrahimi H, Emamian MH, Shariati M, Hashemi H, Fotouhi A. Metabolic syndrome and its risk factors among middle aged population of Iran, a population based study. Diabetes Metab Syndr. 2016;10(1):19-22. [Crossref] [PubMed]
- Tabatabaie AM, Shafiekhani M, Nasihatkon AS, Rastani IM, Tabatabaie M, Barzoo AR, et al. Prevalence of metabolic syndrome in adult population in Shiraz, southern Iran. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2015;9(3):S153-6. [Crossref] [PubMed]
- Sattar N, Gaw A, Scherbakova O, Ford I, O'Reilly DSJ, Haffner SM, et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation. 2003;108(4):414-9. [Crossref] [PubMed]
- Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA. 2002;288(21):2709-16. [Crossref] [PubMed]
- Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988;37(12):1595-607. [Crossref] [PubMed]
- Aghazadeh-Attari J, Mansorian B, Aghazadeh-Attari MM, Ahmadzadeh J, Mohebbi I. Association between metabolic syndrome and sensorineural hearing loss: a cross-sectional study of 11,114 participants. Diabetes Metab Syndr Obes. 2017;10:459-65. [Crossref] [PubMed] [PMC]
- Kang SH, Jung DJ, Cho KH, Park JW, Lee KY, Do JY. Association between sarcopenia and hearing thresholds in postmenopausal women. Int J Med Sci. 2017;14(5):470-6. [Crossref] [PubMed] [PMC]
- Sun YS, Fang WH, Kao TW, Yang HF, Peng TC, Wu LW, et al. Components of metabolic syndrome as risk factors for hearing threshold shifts. PLoS One. 2015;10(8):e0134388. [Crossref] [PubMed] [PMC]
- Cherian KE, Kapoor N, Mathews SS, Paul TV. Endocrine glands and hearing: auditory manifestations of various endocrine and metabolic conditions. Indian J Endocrinol Metab. 2017;21(3):464-9. [Crossref] [PubMed] [PMC]
- Lee Y, Park M. Relationships among factors relevant to abdominal fat and age-related hearing loss. Clin Exp Otorhinolaryngol. 2017;10(4):309-14. [Crossref] [PubMed] [PMC]
- Lee HY, Choi YJ, Choi HJ, Choi MS, Chang DS, Kim AY, et al. Metabolic syndrome is not an independent risk factor for hearing impairment. J Nutr Health Aging. 2016;20(8):816-24. [Crossref] [PubMed]
- Kang SH, Jung DJ, Cho KH, Park JW, Lee KY, Do JY. Association between HbA1c level and hearing impairment in a nondiabetic adult population. Metab Syndr Relat Disord. 2016;14(2):129-34. [Crossref] [PubMed]
- Zhao J, Zhang M, Li Y, Zhang J, Wang N, Yang X. [Association between metabolic syndrome and its components with presbycusis[. Wei Sheng Yan Jiu. 2015;44(4):538-42, 548. [PubMed]
- Chien CY, Tai SY, Wang LF, Hsi E, Chang NC, Wu MT, et al. Metabolic syndrome increases the risk of sudden sensorineural hearing loss in Taiwan: a case-control study. Otolaryngol Head Neck Surg. 2015;153(1):105-11. [Crossref] [PubMed]
- Kim TS, Park SW, Kim DY, Kim EB, Chung JW, So HS. Visceral adipose tissue is significantly associated with hearing thresholds in adult women. Clin Endocrinol (Oxf). 2014;80(3):368-75. [Crossref] [PubMed]
- Masindova I, Varga L, Stanik J, Valentinova L, Profant M, Klimes I, et al. Molecular and hereditary mechanisms of sensorineural hearing loss with focus on selected endocrinopathies. Endocr Regul. 2012;46(3):167-86. [Crossref] [PubMed]
- Carpinelli MR, Wise AK, Burt RA. Vitamin D-deficient diet rescues hearing loss in Klotho mice. Hear Res. 2011;275(1-2):105-9. [Crossref] [PubMed]
- Kucur C, Kucur SK, Gozukara I, Seven A, Yuksel KB, Keskin N, et al. Extended high frequency audiometry in polycystic ovary syndrome. ScientificWorldJournal. 2013;2013:482689. [Crossref] [PubMed] [PMC]
- Mitchell P, Gopinath B, McMahon CM, Rochtchina E, Wang JJ, Boyages SC, et al. Relationship of type 2 diabetes to the prevalence, incidence and progression of age-related hearing loss. Diabet Med. 2009;26(5):483-8. [Crossref] [PubMed]
- Shi DZ, Zou SC, Ai WB. [Clinical characteristics and prognostic analysis of sudden sensorineural hearing loss with metabolic syndrome]. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2019;33(1):63-6. [PubMed]
- Shim HS, Shin HJ, Kim MG, Kim JS, Jung SY, Kim SH, et al. Metabolic syndrome is associated with hearing disturbance. Acta Otolaryngol. 2019;139(1):42-7. [Crossref] [PubMed]
- Jung SY, Shim HS, Hah YM, Kim SH, Yeo SG. Association of metabolic syndrome with sudden sensorineural hearing loss. JAMA Otolaryngol Head Neck Surg. 2018;144(4):308-14. [Crossref] [PubMed] [PMC]
- Jalali MM, Nasimidoust Azgomi M. Metabolic syndrome components and sudden sensorineural hearing loss: a case-control study. Eur Arch Otorhinolaryngol. 2020;277(4):1023-9. [Crossref] [PubMed]
- Grundy SM, Cleeman JI, Merz CNB, Jr HBB, Clark LT, Hunninghake DB, et al; National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110(2):227-39. [Crossref] [PubMed]
- Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans affairs high-density lipoprotein cholesterol intervention trial study group. N Engl J Med. 1999;341(6):410-8. [Crossref] [PubMed]
- Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J, RIO-North America Study Group. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA. 2006;295(7):761-75. [Crossref] [PubMed]
- Kepekçi AH, Köker Y. [Results of the survey carried out with ENT specialists and residents regarding stem cell transplantation and its use in sensorineural hearing loss]. J Contemp Med. 2018;8(4):339-44.
.: İşlem Listesi